Similar Items: First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
- Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
- Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
- PD-L1 expression patterns in stage IB1 cervical squamous cell carcinoma: a retrospective study on implications for tumor budding and immune microenvironment
- A Case of Esophageal Squamous Cell Carcinoma in situ Arising from Esophageal Squamous Papilloma
- A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors
- The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application